GPT-Rosalind Is Not a Clinical Trial Tool. It Is a Clinical Trial Problem.
Clinical operations leaders are not prepared for the downstream impact of GPT-Rosalind. Explore the hidden trial infrastructure risks of...
Clinical operations leaders are not prepared for the downstream impact of GPT-Rosalind. Explore the hidden trial infrastructure risks of...
QMENTA Co-Founder Paulo Rodrigues shares observations from LSX World Congress Europe 2026: why biotech's bottleneck is execution, not science, and...
Multi-site imaging clinical trials face harmonization, QC, and compliance risks. Learn proven solutions for enterprise trial teams and core labs.
Learn the 5 critical success factors clinical directors need to run multi-site neuroimaging trials—covering protocol standardization, QC, training,...
Learn the key challenges of medical AI validation and how cloud-based platforms streamline AI validation medical imaging workflows for clinical...
RSNA 2025 highlighted a crowded AI landscape—but also the growing complexity of multi-site imaging trials. Learn why scanner variability, protocol...
5 warning signs your imaging core facility has outgrown its data infrastructure — from data detective syndrome to compliance gaps — and how modern...
Boston, MA, 29/11/21 QMENTA announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its QMENTA Platform for...
The importance of Data Protection and Data Integrity in Imaging Clinical Trials